12 Analysts Have This To Say About Sarepta Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:SRPT), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased by 3.76% to $164.08. Analysts have provided various ratings and price targets, reflecting their perceptions of the company's market position and financial performance.
May 20, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sarepta Therapeutics has received a mix of bullish and somewhat bullish ratings from 12 analysts over the past three months. The average 12-month price target has increased by 3.76% to $164.08, indicating positive sentiment among analysts.
The majority of analysts have given bullish or somewhat bullish ratings, and the average price target has increased, indicating positive sentiment. This is likely to have a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100